Veru value up 200% on sabizabulin data in COVID-19
Miami, USA-based Veru Healthcare (Nasdaq: VERU) has announced positive efficacy and safety results from a planned interim analysis of the Phase III COVID-19 trial evaluating oral sabizabulin 9mg versus placebo in 150 hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS).
The Independent Data Safety Monitoring Committee unanimously recommended that the study be halted early due to efficacy, and it further remarked that no safety concerns were identified.
"We strongly believe that sabizabulin can be that greatly needed oral therapy for hospitalized moderate to severe COVID-19 patients"This news has sent shares in Veru skywards, and they were almost 200% higher at $13 the mid-point of Monday’s trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze